Rambam Medical Center
Haifa, Israel
31 recruiting
Showing 1–20 of 52 trials
Recruiting
Phase 2
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Pancreatic Acinar Cell CarcinomaResectable Pancreatic CarcinomaResectable Pancreatic Adenocarcinoma+4 more
National Cancer Institute (NCI)152 enrolled453 locationsNCT04858334
Recruiting
Phase 2
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
Primary Biliary CholangitisPBC
Mirum Pharmaceuticals, Inc.260 enrolled130 locationsNCT05050136
Recruiting
Phase 1Phase 2
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
B Cell Precursor Acute Lymphoblastic Leukemia
Amgen281 enrolled109 locationsNCT04521231
Recruiting
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
Systemic Lupus Erythematosus (SLE)
Bristol-Myers Squibb223 enrolled54 locationsNCT07175285
Recruiting
Phase 3
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
Glioblastoma
NovoCure GmbH741 enrolled93 locationsNCT06556563
Recruiting
Phase 3
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Amgen304 enrolled192 locationsNCT04994717
Recruiting
Phase 3
Extension Study for the Port Delivery System With Ranibizumab (Portal)
Hoffmann-La Roche1,000 enrolled165 locationsNCT03683251
Recruiting
Phase 2
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Parkinson DiseaseParkinsonParkinson Disease, Idiopathic+2 more
Neuron23 Inc.150 enrolled70 locationsNCT06680830
Recruiting
Phase 1Phase 2
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
Advanced Liver Cancers
Hoffmann-La Roche518 enrolled33 locationsNCT04524871
Recruiting
Phase 1Phase 2
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Non-small Cell Lung Cancer
Hoffmann-La Roche320 enrolled71 locationsNCT05789082
Recruiting
Phase 1Phase 2
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Relapsed Hematologic MalignancyRefractory Hematologic MalignancyRelapsed Primary Central Nervous System Lymphoma+1 more
Curis, Inc.152 enrolled45 locationsNCT03328078
Recruiting
Phase 3
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
GliomaH3 K27M
Jazz Pharmaceuticals510 enrolled162 locationsNCT05580562
Recruiting
Phase 1Phase 2
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
Hoffmann-La Roche316 enrolled31 locationsNCT04802759
Recruiting
Phase 2
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Carcinoma, Non-Small Cell Lung
Janssen Research & Development, LLC520 enrolled110 locationsNCT05498428
Recruiting
Phase 3
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Janssen Research & Development, LLC1,590 enrolled263 locationsNCT05552222
Recruiting
Phase 2
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Carcinoma, Non-Small Cell Lung
Janssen Research & Development, LLC480 enrolled196 locationsNCT06667076
Recruiting
Phase 3
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Janssen Research & Development, LLC400 enrolled39 locationsNCT07258511
Recruiting
Phase 3
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Leukemia, Myeloid, Acute
Janssen Research & Development, LLC600 enrolled239 locationsNCT06852222
Recruiting
Phase 2
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Hematological Malignancies
Janssen Research & Development, LLC510 enrolled78 locationsNCT04634552
Recruiting
Phase 1Phase 2
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC235 enrolled59 locationsNCT05316155